UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-39695 Delaware 83-4364296 1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317 (Address of principal executive of ices)(Zip Code) (724) 514-180 ...

Key Takeaways Viatris beat Q4 estimates with 57-cent EPS and $3.7B in revenue, up 5% year over year.VTRS saw 8% operational growth in Emerging Markets and Greater China, lifting Brands sales 8%.Viatris guided 2026 revenue to $14.4B-$14.9B and EPS of $2.33-$2.47 after FDA updates.Viatris Inc. (VTRS) delivered fourth-quarter 2025 adjusted earnings per share (EPS) of 57 cents, which beat the Zacks Consensus Estimate of 52 cents. The company recorded an adjusted EPS of 54 cents in the year-ago quarter.Total rev ...

Viatris (VTRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.62%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.63 per share when it actually produced earnings of $0.67, delivering a surprise of +6.35%.Over the last four quarters, the compan ...

Viatris (NasdaqGS:VTRS) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAsh Verma - Executive Director, SMID Biotech and BiopharmaBill Szablewski - Head of Capital MarketsCorinne Le Goff - Chief Commercial OfficerDoretta Mistras - CFOPhilippe Martin - Chief R&D OfficerScott Smith - CEOUmer Raffat - Senior Managing DirectorConference Call ParticipantsChris Schott - Managing Director and Senior Equity Research AnalystDavid Amsellem - Managing Director, Senior Research AnalystDennis Din ...

Viatris (NasdaqGS:VTRS) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAsh Verma - Executive Director, SMID Biotech and BiopharmaBill Szablewski - Head of Capital MarketsCorinne Le Goff - Chief Commercial OfficerDoretta Mistras - CFOPhilippe Martin - Chief R&D OfficerScott Smith - CEOUmer Raffat - Senior Managing DirectorConference Call ParticipantsChris Schott - Managing Director and Senior Equity Research AnalystDavid Amsellem - Managing Director, Senior Research AnalystDennis Din ...

Viatris (NasdaqGS:VTRS) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker10Good morning, and welcome to the Viatris Q4 2025 earnings call. Today, all participants are in a listen-only mode. Should you need assistance during today's call, please signal for a conference specialist by pressing the star key, followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on your touchtone phone. To withdraw your question, please p ...

Viatris forecasts 2026 profit below estimates on India manufacturing woes | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[Viatris Inc]Follow[Pfizer Inc]FollowFeb 26 (Reuters) - Drugmaker Viatris [(VTRS.O), opens new tab] forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations.A fire occurred at the company's manufacturing facility in Nashik, ...

Q4 & Full Year 2025 Earnings February 26, 2026 © 2026 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about: 2026 financial guidance; enterprise-wide strategic review ...

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results PITTSBURGH – February 26, 2026 – Viatris Inc. (Nasdaq: VTRS) today announced robust financial results for the fourth quarter and full year 2025. The Company also announced it has completed its enterprise-wide strategic review and expects to deliver meaningful net cost savings while enabling reinvestment in areas that enhance the growth profile and long-term competitiveness of the Company. Executive Commentary "2025 was a year of strong exec ...

Core Insights - Viatris reported strong financial results for Q4 and full year 2025, with total revenues of $3.7 billion for Q4 and $14.3 billion for the full year, meeting or exceeding financial guidance across all key metrics [1][2][3] - The company completed an enterprise-wide strategic review, expecting to deliver $650 million in total cost savings while reinvesting up to $250 million over the next three years [1][3] - Viatris anticipates regulatory decisions for six product candidates in 2026 and multiple important pipeline milestones, positioning itself for sustainable growth [1][3] Financial Performance - Q4 2025 total revenues increased by 5% compared to Q4 2024, while full year revenues decreased by 3% compared to 2024 [2][3] - U.S. GAAP net loss for Q4 2025 was $340.1 million, a 34% improvement from a loss of $516.5 million in Q4 2024 [2][3] - Adjusted net earnings for Q4 2025 were $658.7 million, with adjusted EPS of $0.57, reflecting a 6% increase from Q4 2024 [2][3] Strategic Initiatives - The company initiated restructuring activities as part of its strategic review, expecting a global workforce reduction of up to 10% [3][6] - Total pre-tax charges related to restructuring are estimated between $700 million and $850 million, with anticipated savings of $600 million to $700 million once fully implemented [3][6] - Viatris plans to provide a balanced capital allocation approach for 2026, returning over $1 billion to shareholders in 2025 [1][3] Product Pipeline and Regulatory Updates - The company generated approximately $78 million in new product revenues in Q4 2025, with expectations of $450 million to $550 million in new product revenues for 2026 [2][3] - Viatris has several regulatory submissions under review, including a J-NDA for pitolisant in Japan and an NDA for a low-dose estrogen weekly patch in the U.S. [2][6] - The FDA has assigned a PDUFA goal date of July 30, 2026, for the low-dose estrogen patch and October 17, 2026, for MR-141 [6] Market Performance - Generics net sales were impacted by competition in North America and government price regulations in Japan, while brands net sales showed strength in Greater China and Emerging Markets [2][3] - The company expects continued operational growth driven by its base business and net cost savings in 2026 [1][3]